Dr. Riedel is executive chairman and former chief executive officer of Aptinyx. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals, Cerevel Therapeutics, Eton Pharmaceuticals, and the Illinois Biotechnology Innovation Organization. He served on the board of directors of Ariad Pharmaceuticals until the company was acquired in February 2017. Dr. Riedel is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council. He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine and, prior to moving into industry, was an associate professor of medicine at Boston University School of Medicine and a visiting professor at the Massachusetts Institute of Technology. Dr. Riedel received a Diploma and Ph.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University.

Mr. Kidd is president and chief executive officer of Aptinyx, as well as a member of the company’s board of directors. Prior to joining Aptinyx in 2017 as chief commercial officer and then chief operating officer, he was with Baxter International for over ten years, most recently as senior vice president of strategy and business development. Previously he held a number of commercial leadership positions including general manager of Baxter Canada, global franchise head for surgical care, and general manager of US anesthesia and cardiovascular. Before joining Baxter he worked at Boston Consulting Group both in London and then Chicago focused on pharmaceutical and other healthcare clients. Mr. Kidd received a BM BCh medical degree from the University of Oxford and a BA in medical sciences from the University of Cambridge.

Molly Dir is vice president of human resources at Aptinyx. She joined the company in 2021 and brings more than 20 years of HR leadership from across the biopharmaceutical industry. Prior to joining Aptinyx, she held multiple roles of increasing responsibility at Takeda, where she served as Chief of Staff to the president of the U.S. commercial business unit, helping to facilitate the integration of Takeda and Shire as well as the company’s relocation to Boston. While at Takeda, Ms. Dir also worked as Vice President and Head of Strategic Talent, Diversity & Inclusion and was responsible for the development and execution of all talent programs within the US commercial business unit. She served as Vice President and Head of Global R&D HR, leading a team of 50 global HR professionals and supporting Takeda’s global research and development, including an employee group of 4,500 across the U.S., Europe, and Asia. Ms. Dir began her career in life sciences HR in the Pharmaceutical Development Division of Abbott. She holds a Bachelor of Arts degree in Organizational and Interpersonal Communications from Loyola University of Chicago.

Mr. Estupinan is vice president of finance and accounting and controller at Aptinyx, with responsibilities that include developing, executing, and overseeing the accounting and financial processes to support the company. Mr. Estupinan was part of the team at the predecessor company, Naurex, and has been with Aptinyx since the formation of the company. In his previous position at Aptinyx, as senior director of finance and accounting, he played a lead role in the IPO of the company in 2018. Prior, he was the finance reporting manager at Naurex and was involved in the acquisition of the company by Allergan. Before joining Naurex, Mr. Estupinan held roles of increasing responsibility at Durata Therapeutics and Abbott Laboratories. Mr. Estupinan began his career at Deloitte. He holds a B.A. with concentration in finance and accounting from Indiana University, Fort Wayne and earned his CPA in Indiana.

Dr. Khan is vice president of chemistry research and development at Aptinyx. Prior to Aptinyx, he was vice president of chemistry research and development at Naurex. Dr. Khan has over 20 years’ experience as a senior chemist at several biotechnology companies, including Elan and Gliatech. Dr. Khan has discovered and developed multiple novel central nervous system molecules that have entered human clinical trials, including many NMDA receptor modulators. Dr. Khan received a B.S. and B.Ed. from the Regional Institute of Education, Bhopal, India, and an M.S. and Ph.D. from Kanpur University in India. He was a postdoctoral fellow at the Indian Institute of Technology, Kanpur, India.

Mr. Khanna is chief financial officer and chief business officer of Aptinyx, with responsibilities that include finance, corporate and business development, alliance management, legal, and communications. He was previously vice president of corporate development at Naurex and managed its financing and transaction efforts, culminating in the company’s acquisition by Allergan. Prior to Naurex, Mr. Khanna served as director of business development at Vanda Pharmaceuticals. He was formerly a member of the cardiology strategic marketing team at Cordis Corporation, a Johnson & Johnson company. Earlier, Mr. Khanna was a strategy consultant with the Palladium Group and with the Strategic Advisory Services practice of Ernst & Young (now Capgemini). He serves on the board of directors of the Illinois Biotechnology Innovation Organization. Mr. Khanna received a B.S. in finance and B.A.S. in systems engineering from the University of Pennsylvania, as well as an M.B.A. from the Wharton School.

Dr. King is senior vice president, clinical and CMC operations at Aptinyx. Prior to joining Aptinyx, she served in senior leadership roles at Levo Therapeutics, AbbVie, Takeda, Veeva Systems, and Abbott, where she was responsible for clinical projects and various global functions. Dr. King teaches courses in the clinical research and regulatory compliance program at the University of Chicago Graham School. She earned a B.S. in biochemistry from the University of Notre Dame and later received an M.A. in Health Care Ethics and a Ph.D. in Philosophy from Loyola University in Chicago.

Dr. Harald Murck is vice president, clinical & medical affairs at Aptinyx. He has more than 20 years of experience working with both small biotech and large pharmaceutical companies, including Amarin, Novartis, BMS, Axovant, Acorda Therapeutics, PTC Therapeutics, and Sage Therapeutics. He oversaw and was a key contributor to the development of compounds in psychiatric indications (major depression, schizophrenia, central pain disorders, cognitive dysfunction) and movement disorders (Huntington’s disease and Parkinson’s disease). Dr. Murck has extensive experience in early- and late-stage clinical development and has a passion for translational research. He is a psychiatrist and psychotherapist who trained at the Max-Planck-Institute of Psychiatry in Munich, Germany. Dr. Murck has been involved in NMDA-related research since the 1990s. He holds an academic affiliation at the Philipps-University, Marburg, Germany, where he mentors MD students in active research projects and is the author of 85 peer reviewed scientific articles and several book chapters.